What is VIP (Vasoactive Intestinal Peptide)?

VIP is a naturally occurring 28-amino-acid signalling peptide found throughout the body, particularly in the nervous system, gut, lungs, and immune tissue. It acts as a vasodilator and as a neuroendocrine and immune-modulating messenger through the VPAC1 and VPAC2 receptors.

What does research suggest about VIP?

VIP's physiology is well characterised in animal and in-vitro studies, which describe its roles in vasodilation and immune and neuroendocrine signalling. Human evidence is limited outside specific medical and diagnostic contexts, so many informal claims go beyond what published clinical trials support.

Is VIP an approved medicine?

VIP is not an approved general-use medicine. It is used in certain specific medical and diagnostic settings, but it is not a broadly authorised treatment, and its use outside those contexts is not supported by regulatory approval.

VIP can meaningfully affect blood pressure due to its vasodilatory action, so it is considered appropriate only under medical supervision. It is not a compound suited to casual or unsupervised use.

What are the known side effects of VIP?

Reported effects include flushing and blood-pressure changes related to its vasodilatory activity. Because human data are limited, the full side-effect profile in non-clinical use is not well established.

What is the legal status of VIP?

VIP is treated as a restricted compound and is not an approved general-use medicine. Legal and regulatory status varies by jurisdiction, and it is typically confined to specific medical or diagnostic uses rather than general availability.

Is VIP the same thing as "aviptadil" that appears in clinical trials?

Aviptadil is a synthetic version of vasoactive intestinal peptide developed as an investigational drug. So they share the same peptide sequence, but "VIP" usually refers to the endogenous signalling molecule studied in physiology, while aviptadil is the branded pharmaceutical form tested in formal trials. Neither is an approved general-use medicine outside specific investigational or medical settings.

Why is VIP considered a "restricted" or non-casual compound compared with other peptides?

Unlike peptides discussed mainly for cosmetic or exploratory purposes, VIP directly affects vasculature and can influence blood pressure, which is why it is described as appropriate only under medical supervision. Its physiology is well characterized precisely because it is a potent signalling molecule, and that potency is the reason it is not treated as a low-stakes research curiosity.

Is VIP a well-understood molecule or something newly discovered?

A common misconception is that VIP is a novel "research peptide." In fact it was first isolated in 1970 and is one of the more thoroughly studied endogenous peptides in physiology, with decades of work on its receptors and signalling. What remains limited is high-quality controlled human evidence for the niche uses it is sometimes discussed for, not the basic biology itself.

Where can I buy VIP and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Immune / Neuro

Buy VIP – Vendors, Prices, Testing and Evidence

Buy VIP

Also known as: Vasoactive Intestinal Peptide

Evidence grade C — Early / PreclinicalRisk flag

Short answer

A signalling peptide discussed in niche protocols. Affects vasculature and immune signalling; not a casual compound.

Where can you buy VIP?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

VIP is an endogenous peptide with roles in vasodilation and immune/neural signalling.

What is not established?

Limited outside specific medical contexts.

Safety

Can affect blood pressure; appropriate only under medical supervision.

Regulatory status

Not an approved general-use medicine; used in specific medical/diagnostic contexts.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy VIP: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	VIP research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

VIP research product

Code PEPTIDES10 −10% · discount code details

What is it?

VIP is an endogenous peptide with roles in vasodilation and immune/neural signalling.

Research and evidence

Vasoactive Intestinal Peptide (VIP) is a naturally occurring 28-amino-acid signalling peptide produced throughout the human nervous system, gut, lungs, and immune tissues. First isolated from intestinal extracts, it belongs to the secretin-glucagon peptide family and acts through the VPAC1 and VPAC2 receptors. Physiologically, VIP is best known for two roles: it is a potent vasodilator that relaxes smooth muscle and widens blood vessels, and it functions as a neuroendocrine and immune-modulating messenger. Because it is an endogenous molecule with wide-ranging effects on vasculature and immune signalling, VIP is not a casual research compound. It is discussed almost entirely in specialised medical, diagnostic, and preclinical contexts rather than in general wellness use.

Interest in VIP centres on its influence on immune and neural pathways. Its physiology is well characterised in animal and laboratory studies, where researchers have mapped how it modulates inflammatory signalling, smooth-muscle tone, and neuroendocrine function. Human data, however, remain limited outside of specific clinical and diagnostic settings, and much of what circulates in informal or niche protocols extrapolates well beyond the published clinical evidence. On the honest evidence spectrum, VIP sits at a lower tier: mechanistically well understood and physiologically important, but without broad, high-quality human trials supporting the informal uses it is sometimes associated with.

Safety is a central consideration with VIP because its vasodilatory action can meaningfully affect blood pressure and produce flushing. For that reason it is appropriate only under medical supervision, and it is not an approved general-use medicine. This page is an educational reference intended to summarise what VIP is, what the research does and does not show, and where its status remains restricted or preclinical. It is not medical advice and does not describe dosing, protocols, or sourcing.

Evidence grade: C

Limited outside specific medical contexts. Well characterised physiologically.

Human evidence

Limited outside specific medical contexts.

Animal and preclinical evidence

Well characterised physiologically.

Proposed mechanisms

Vasodilation
Immune and neuroendocrine signalling

Safety concerns and known side effects

Can affect blood pressure; appropriate only under medical supervision.

Flushing
Blood-pressure effects

Regulatory status

Not an approved general-use medicine; used in specific medical/diagnostic contexts.

VIP research timeline

1970
Vasoactive intestinal peptide is first isolated from intestinal tissue by Said and Mutt, who named it for its blood-vessel-relaxing (vasodilatory) activity.
1970s
Its amino-acid sequence is determined and it is recognized as a member of the secretin/glucagon peptide family with broad roles in the gut, nervous system, and circulation.
1980s-1990s
Receptors (later classified VPAC1 and VPAC2) are characterized and VIP's roles in vasodilation, smooth-muscle relaxation, and immune and neuroendocrine signalling are mapped in extensive preclinical work.
2000s
Anti-inflammatory and immune-modulating effects of VIP are described in laboratory and animal models, drawing interest in autoimmune and inflammatory contexts.
2010s
Aviptadil, a synthetic form of VIP, is investigated in clinical trials for conditions such as pulmonary hypertension and acute lung injury; VIP also appears in niche off-label protocols despite thin controlled human evidence.
early 2020s
Aviptadil received emergency/investigational attention for severe respiratory illness, but trial results were mixed and it has not become an approved general-use medicine.

Frequently asked questions about VIP

What is VIP (Vasoactive Intestinal Peptide)?: VIP is a naturally occurring 28-amino-acid signalling peptide found throughout the body, particularly in the nervous system, gut, lungs, and immune tissue. It acts as a vasodilator and as a neuroendocrine and immune-modulating messenger through the VPAC1 and VPAC2 receptors.
What does research suggest about VIP?: VIP's physiology is well characterised in animal and in-vitro studies, which describe its roles in vasodilation and immune and neuroendocrine signalling. Human evidence is limited outside specific medical and diagnostic contexts, so many informal claims go beyond what published clinical trials support.
Is VIP an approved medicine?: VIP is not an approved general-use medicine. It is used in certain specific medical and diagnostic settings, but it is not a broadly authorised treatment, and its use outside those contexts is not supported by regulatory approval.
Is VIP safe?: VIP can meaningfully affect blood pressure due to its vasodilatory action, so it is considered appropriate only under medical supervision. It is not a compound suited to casual or unsupervised use.
What are the known side effects of VIP?: Reported effects include flushing and blood-pressure changes related to its vasodilatory activity. Because human data are limited, the full side-effect profile in non-clinical use is not well established.
What is the legal status of VIP?: VIP is treated as a restricted compound and is not an approved general-use medicine. Legal and regulatory status varies by jurisdiction, and it is typically confined to specific medical or diagnostic uses rather than general availability.
Is VIP the same thing as "aviptadil" that appears in clinical trials?: Aviptadil is a synthetic version of vasoactive intestinal peptide developed as an investigational drug. So they share the same peptide sequence, but "VIP" usually refers to the endogenous signalling molecule studied in physiology, while aviptadil is the branded pharmaceutical form tested in formal trials. Neither is an approved general-use medicine outside specific investigational or medical settings.
Why is VIP considered a "restricted" or non-casual compound compared with other peptides?: Unlike peptides discussed mainly for cosmetic or exploratory purposes, VIP directly affects vasculature and can influence blood pressure, which is why it is described as appropriate only under medical supervision. Its physiology is well characterized precisely because it is a potent signalling molecule, and that potency is the reason it is not treated as a low-stakes research curiosity.
Is VIP a well-understood molecule or something newly discovered?: A common misconception is that VIP is a novel "research peptide." In fact it was first isolated in 1970 and is one of the more thoroughly studied endogenous peptides in physiology, with decades of work on its receptors and signalling. What remains limited is high-quality controlled human evidence for the niche uses it is sometimes discussed for, not the basic biology itself.
Where can I buy VIP and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

ImmuneNiche protocols

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10